

Federal Court Rules in ICAN's Favor and Orders COVID-19 Safety Data to be Disclosed

By Informed Consent Action Network

Global Research, July 21, 2021

ICAN 20 July 2021

Region: **USA**

Theme: Law and Justice, Science and

Medicine

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at <u>@crg_globalresearch.</u>

After months of NIH objecting, and after seeking Court intervention, ICAN's attorneys have won a motion which now forces the NIH to unredact and disclose safety-related data they tried to withhold from Moderna's Phase 1 clinical trial report.

As a result of a FOIA request, the National Institutes of Health (NIH) provided ICAN a copy of an internal 322-page Safety Summary Report along with over 700 pages of Appendices to that report, detailing safety data from Moderna's Phase I clinical trial for its and NIAID's COVID-19 vaccine. This report was previously shared with ICAN supporters and was the first and only time we are aware of that this report was made public. It can be downloaded <a href="https://example.com/here/beauty-state-new-material-report-state-new-material-re

After reviewing the report, <u>ICAN</u> <u>challenged</u> the redactions made within the document, explaining their importance to the public. NIH <u>fought back</u> but the Court, in its June 24, 2021 <u>decision</u>, ultimately ruled in ICAN's and the public's favor holding that the "NIH cannot articulate a sufficient privacy interest to justify redacting" the information that it did and that "the public interest in seeing the full data outweighs any individual privacy concerns" of the clinical trial participants. The unredacted data will be provided within a few days and ICAN will immediately make it available so that everyone can see what information is being withheld from the public.

ICAN also challenged the adequacy of the agency's search and believes there are likely more responsive documents in NIH's possession. To address this issue, ICAN has now filed additional FOIA requests to obtain copies of these documents, and any new productions will be shared. ICAN will never rest in its fight to expose the truth regarding these products or in demanding full transparency and full informed consent for any and all vaccines, especially as these manufacturers seek FDA licensure for these experimental COVID-19 vaccines.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

The original source of this article is ICAN Copyright © ICAN, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Informed Consent Action Network

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca